日韩成人一区二区三区在线观看,亚洲爆乳成av人在线视菜奈实,一级特黄aaa大片在线观看成人一级片在线观看,欧美一级a视频在线观看,久久综合狠狠色综合伊人,国产亂倫近親相姦视频,日韩免费无码视频一区二区三区,97久久精品亚洲中文字幕无码,久爱无码精品免费视频,超碰97人人模人人爽人人

Gene Therapy
Home > Application > Gene Therapy > Oncolytic Virus

Oncolytic Virus

Oncolytic viruses (OVs) are considered particularly promising because they have two main modes of action: they can both kill infected tumor cells and stimulate antitumor immunity to promote the development of antitumor immunity against uninfected tumor cells. killing. In addition, there are other associated effects. Because of this, they offer the possibility of greatly enhancing existing tumor therapies. However, the history of commercial success associated with oncolytic virus therapy is relatively short. Although some adenovirus-based oncolytic virus therapy has been approved by regulatory agencies in China and other countries earlier, the first one to obtain FDA and EMA approval and cause the industry's broader focus on oncolytic therapies came in 2015 with Amgen's Talimogene laherparepvec (T-VEC), a recombinant HSV-1 oncolytic virus, and the more recent approval was teserpaturev from Daiichi Sankyo. or G47Δ (DELYTACT?), also a modified form of HSV-1, received conditional and time-limited approval in Japan for glioblastoma in June 2021.

 

Although the successful commercialization of oncolytic viruses as immunotherapies is relatively new, the science at their core has a long history, since scientists first observed slowed tumor progression in some patients with live microbial and viral infections. Researchers have already begun to explore viruses as anti-cancer tools. Over the past few decades, this observation of natural pathogens has been applied to a range of engineered viruses, including HSV-1, adenovirus, poliovirus, measles virus, and others. The understanding of how these viruses work is also steadily improving. In addition to approved products, many viral oncolytic therapies built using various viral platforms are currently undergoing clinical trials, many of which have shown promising results.

 

Current research on oncolytic virus design has focused on "arming" oncolytic viruses with various transgenes to increase their immune stimulation, modulate immune checkpoints, and provide imaging targets. By striving to synergize oncolytic viruses with other immunomodulators or cytotoxic agents, developers hope to achieve the most effective tumor immunotherapy. Although researchers are continuing to optimize these viruses and their production through various virus engineering strategies, many goals related to the safety, efficacy, and commercial scale-up of such products are challenging their way forward, including how to achieve high virus yield, highly reproducible critical quality attributes, genetic stability, and formulation and product stability.

 

One challenge that slowing the development of these therapies is ensuring the relative safety of viral vectors. Most oncolytic viruses replicate conditionally or partially mainly in tumor cells, and minimizing the possibility of viral replication in healthy cells is a primary consideration in early clinical trials. This increased safety highlights the importance of the early stages of viral vector design, from cell line selection to infection optimization. For biotherapeutics that can replicate themselves, even those that are restricted to specific cell types or cell cycle stages, ensuring that the virus cannot revert to full replication competence is critical to advancing therapeutics through the development process.


 


 

Virus

DNA

RNA

Adenovirus

Herpes simplex virus

Parvovirus H1

Vaccinia virus

Measles vaccine virus

Newcastle disease virus

Maraba virus

Reovirus

Vesicular stomatitis virus

Pollovirus

Coxsackie viurs


Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Oncolytic Virus

Genome   size

35   kb

154   kb

5   kb

190   kb

16   kb

16   kb

11   kb

23   kb

11   kb

7.5   kb

7.4   kb

Diameter

90-100   nm

200   nm

18-28   nm

70-100   nm

100-200   nm

100-500   nm

70-170   nm

75   nm

80   nm

25-30   nm

22-30   nm

Capsid   symmetry

Icosahedral

Icosahedral

Icosahedral

Complex

Icosahedral

Helical

Helical

Icosahedral

Helical

Icosahedral

Icosahedral

Envelope

Naked

Enveloped

Naked

Complex   coats

Enveloped

Enveloped

Enveloped

Naked

Enveloped

Naked

Naked

Site   of replication

Nucleus   and cytoplasm

Nucleus   and cytoplasm

Nucleus   and cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Cytoplasm

Transgene   capacity

N/A

N/A

Entry   receptor

CAR

HVEM,nectin-1,nectin-2

Sialic   acid residues

No   specific receptor

SLAM和CD46

Sialic   acid containing

proteins

LDLR

No   specific receptor

LDLR

PVR   or CD155

CAR   and CD55

Most-treated   cancer type

Brain   cancer

Skin   cancer

Brain   cancer and pancreatic cancer

Liver   cancer and solid tumors

Breast   cancer

Solid   tumor

NSCLC

Myeloma

Solid   tumors

Melanoma,   glioblastoma,

breast   cancer

Bladder   cancer, lung cancer and melanoma

  

Vector design and engineering, in conjunction with other aspects of early product development, are critical to reducing the possibility of off-target cell replication or expression after a drug product is administered to a patient. Proper vector design is critical. Improperly designed vectors, or the use of non-optimized cell lines, can lead to genetic instability, including the potential to produce fully replicative viruses, as well as the potential to produce transgenic variants or subtypes that affect viral efficacy and safety. Likewise, the impact of cell line selection, culture type, media, supplements, infection optimization, and early downstream harvest processes on virus yield and purity requires an integrated, multifaceted approach. In particular, the choice of media used to grow cells should not affect their safety and productivity, so media selection becomes an important part of ensuring optimal scale-up.

 

Moreover, due to the significant differences among different oncolytic viruses, it is necessary to design a targeted production process according to the characteristics of each virus. In general, however, the virus production process begins with production cell line selection, including growth in adherent or suspension culture, cell lysis, media and buffer optimization, virus purification, and aseptic production, the latter is especially important for viruses with larger particle size. Viruses, such as vaccina, cannot be sterile filtered through the same steps as adenoviruses and other small non-enveloped viruses. As with other viral vector-based products, manufacturing facilities require the highest level of commitment to GMP compliance and sterility, employing single-use technologies and even closed systems wherever possible to prevent any potential cross-contamination.

 

Oncolytic Virus

 

Furthermore, as mentioned previously, since only a few approved oncolytic viral therapies currently exist on the market, the regulatory environment surrounding them remains relatively fluid, and oncolytic viral vector design requires attention to the ever-changing regulatory requirements applicable to these therapies , as each virus used in oncolytic virus applications has unique characteristics, unique approval paths may arise that are specific to different oncolytic virus products based on the chosen virus and mode of action. At the same time, while virus vectors tested for vaccine and oncolytic applications are largely consistent, there are some key differences: Typically, oncolytic viruses have additional active recombinant components, usually immunomodulatory, and thus require more in-depth testing, that is, confirmation of efficacy and safety of oncolytic virus products may require new analytical testing strategies.





Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

久久久精品日本一区二区三区| 亚洲精品无码久久下载| 亚洲一区无码中文字幕乱码| 少妇爽翻喷白浆视频在线观看| 一本久道久久综合狠狠爱| 亚洲AV永久无码精品网站,| 国产精品无码久久av不卡| 吸咬奶头狂揉60分钟视频| 网友分享AV无码高潮AV心得| 精品无码人妻一区二区三区品| 精品久久久久中文字幕日本| 99久久麻豆AV一二三区| 婷婷激情综合网亚州五月中文字幕 | 日本在线看片人成视频1000| 亚洲天堂在线观看视频网站| 久久精品国产亚洲AV大全| 重口SM一区二区三区视频| 女儿的朋友7中汉字晋通话| 一级特黄高清aaaa大片| 亚洲AV无码一区二区三区少妇o| 中文乱码人妻系列一区二区| 日韩精品中文一区二区| 国产精品一区二区在线观看99| 欧美亚洲综合在线观看| 免费精品无码AV片在线观看| 国产SUV精品一区二区6| 狠狠躁夜夜躁人人爽天天开心婷婷| 文国产成人久久精品流白浆| 国产精品永久免费,亚洲国产精品尤物YW在线观看| 日韩乱码精品一区二区中文字幕| 另类一区二区在线亚洲精品| 精品人妻无码专区中文字幕| 在线免费视频人妻| 久精品国产亚洲Av高清| 久久99国产综合精品| 天天爽夜夜爽人人爽一区二区| 精品久久人人爽天天玩人人妻| 久久久久免费精品视频| 精品人妻系列无码天堂| 精品人妻无码专区中文字幕| 久久久久久久综合色一本|